Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$26.33 USD

26.33
304,606

+0.83 (3.25%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $26.36 +0.03 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PCRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Pacira BioSciences, Inc. [PCRX]

Reports for Purchase

Showing records 701 - 717 ( 717 total )

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 701

01/06/2012

Daily Note

Pages: 5

We See Reduced Competitive Risk as Potential Competitor, Posidur, Misses Phase 3 Endpoint. Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 702

12/19/2011

Daily Note

Pages: 5

EXPAREL Pivotal Trial Data Published in Medical Journal Ahead of Anticipated Launch in January 2012. Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 703

12/02/2011

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 704

11/28/2011

Company Report

Pages: 8

Recent Financing Extends Cash Runway Through Commercial Launch and Potential Breakeven. Reiterate OUTPERFORM and Adjusting FV to $16.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 705

10/31/2011

Company Report

Pages: 8

EXPAREL Approved For Postsurgical Pain Management and Launch Expected In January 2012

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 706

10/25/2011

Daily Note

Pages: 5

We Are Optimistic for Potential EXPAREL Approval by the PDUFA Date of this Friday, October 28th. Reiterate OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 707

10/19/2011

Daily Note

Pages: 5

New Data Shows Reduction in Opioid Burden with Exparel

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 708

10/10/2011

Industry Report

Pages: 21

Q4 2011 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 709

09/26/2011

Daily Note

Pages: 5

Exparel Use in Plastic Surgery Highlighted at Medical Conference

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 710

09/06/2011

Company Report

Pages: 4

Commercial Strategy Progresses with New Marketing and Logistics Agreements Ahead of Important October 28 PDUFA Date for Exparel

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 711

09/02/2011

Industry Report

Pages: 5

LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of September 4

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 712

08/11/2011

Company Report

Pages: 9

Q2 Financials Uneventful

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 713

06/14/2011

Company Report

Pages: 9

Exparel PDUFA Date Extended by Three Months to October 28th

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 714

05/23/2011

Company Report

Pages: 4

Presentation of program-wide safety data for Exparel supports potential FDA approval, in our view.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 715

05/11/2011

Company Report

Pages: 9

Q1 Financials: Pre-Launch Activities Continue to Progress Ahead of July 28 PDUFA for Exparel

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 716

03/31/2011

Company Report

Pages: 10

2010 Financials a Non-Event. We See a Major Value Driver Mid-Year with the July 28 PDUFA Date for Exparel

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 717

03/15/2011

Company Report

Pages: 21

Initiating Coverage with an OUTPERFORM Rating and $19 Fair Value

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 75.00

Research Provided by a Third Party